Fulcrum Therapeutics and Slate Medicines Announce Definitive All-Stock Merger With $245M Private Placement

Fulcrum Therapeutics and Slate Medicines entered into a definitive all-stock merger agreement to combine into a Nasdaq-listed biotechnology company operating as Slate Medicines under ticker SLTE. The transaction is supported by an oversubscribed concurrent $245 million private placement led by Frazier Life Sciences, with committed participation from multiple healthcare investors and expected to fund operations into 2029.